Drug Approval | March 09, 2024
Dishman Carbogen Amcis updates on USFDA inspection at its Bavla facility
The inspection was concluded with few procedural observations
The inspection was concluded with few procedural observations
The company will provide comprehensive response to USFDA for the observations
The plan is to set up an ultramodern Solvent Recovery Plant for third party purposes
The facility will manufacture Specialty and Fine Chemicals tailored to various applications across industries such as Polymer and Water Treatment facilities
The facility will accommodate over 1,500 employees
The observations do not pose any risk to site's compliance standards or its business continuity
GMP certification helps enable biotechnology customers to accelerate accessibility of new RNA-based therapies for patients
The unit’s contribution to the company's revenue US$3.85 million in the last fiscal year
The plant is yet to start commercial operations
This development is a strategic part of the company's commitment to bolstering its position in the advanced pharmaceutical intermediates segment
Subscribe To Our Newsletter & Stay Updated
